HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells

Neoplasia (United States)

Volumn 15, Issue 3, 2013, Pages 263-280

  Natarajan, Suchitra ^a   Hombach Klonisch, Sabine ^a   Dröge, Peter ^b   Klonisch, Thomas ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; CASPASE 3; CASPASE 7; CHECKPOINT KINASE 1; CHECKPOINT KINASE RAD3; HIGH MOBILITY GROUP A2 PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; CELL CYCLE CHECKPOINT; CELL SURVIVAL; COMET ASSAY; CONTROLLED STUDY; DENSITOMETRY; DNA DAMAGE; DNA REPAIR; FIBROSARCOMA; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; NEOPLASM; PHOSPHORYLATION; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 84874624291     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121988     Document Type: Article

References (73)

1. Reeves R and Nissen MS (1990). The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 265, 8573-8582.
2. Gattas GJF, Quade BJ, Nowak RA, and Morton CC (1999). HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 25, 316-322.
3. Liau S-S and Whang E (2008). HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 14, 1470-1477.
4. Park S-M, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, and Peter ME (2007). Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6, 2585-2590.
5. Summer H, Li O, Bao Q, Zhan L, Peter S, Sathiyanathan P, Henderson D, Klonisch T, Goodman SD, and Dröge P (2009). HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. Nucleic Acids Res 37, 4371-4384.
6. Chieffi P, Battista S, Barchi M, Di Agostino S, Pierantoni GM, Fedele M, Chiariotti L, Tramontano D, and Fusco A (2002). HMGA1 and HMGA2 protein expression in mouse spermatogenesis. Oncogene 21, 3644-3650.
7. Zhou X, Benson KF, Ashar HR, and Chada K (1995). Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376, 771-774.
8. Battista S, Fidanza V, Fedele M, Klein-Szanto AJP, Outwater E, Brunner H, Santoro M, Croce CM, and Fusco A (1999). The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 59, 4793-4797.
9. Zaidi MR, Okada Y, and Chada KK (2006). Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res 66, 7453-7459.
10. Li O, Vasudevan D, Davey CA, and Dröge P (2006). High-level expression of DNA architectural factor HMGA2 and its association with nucleosomes in human embryonic stem cells. Genesis 44, 523-529.
11. Li O, Li J, and Dröge P (2007). DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells. FEBS Lett 581, 3533-3537.
12. Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R, and Resar LMS (2008). HMGA2 participates in transformation in human lung cancer. Mol Cancer Res 6, 743-750.
13. Fusco A and Fedele M (2007). Roles of HMGA proteins in cancer. Nat Rev Cancer 7, 899-910.
14. Wood LJ, Maher JF, Bunton TE, and Resar LMS (2000). The oncogenic properties of the HMG-I gene family. Cancer Res 60, 4256-4261.
15. Fedele M and Fusco A (2010). HMGA and cancer. Biochim Biophys Acta (BBA) 1799, 48-54.
16. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, and Bullerdiek J (1997). Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 19, 153-156.
17. Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, and Bullerdiek J (2007). HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 46, 503-511.
18. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, and Imai K (2004). Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 64, 2024-2029.
19. Mayr C, Hemann MT, and Bartel DP (2007). Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315, 1576-1579.
20. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, et al. (2007). let-7 Regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123.
21. Dröge P and Davey CA (2008). Do cells let-7 determine stemness? Cell Stem Cell 2, 8-9.
22. Lim D-S, Kim S-T, Xu B, Maser RS, Lin J, Petrini JHJ, and Kastan MB (2000). ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404, 613-617.
23. Cha RS and Kleckner N (2002). ATR homolog Mec1 promotes fork progression, thus averting breaks in replication slow zones. Science 297, 602-606.
24. Byun TS, Pacek M, Yee M-C, Walter JC, and Cimprich KA (2005). Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes Dev 19, 1040-1052.
25. Ward IM, Minn K, and Chen J (2004). UV-induced ataxia-telangiectasiamutated and Rad3-related (ATR) activation requires replication stress. J Biol Chem 279, 9677-9680.
26. Bartek J, Lukas C, and Lukas J (2004). Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5, 792-804.
27. Lambert S and Carr AM (2005). Checkpoint responses to replication fork barriers. Biochimie 87, 591-602.
28. Shirahige K, Hori Y, Shiraishi K, Yamashita M, Takahashi K, Obuse C, Tsurimoto T, and Yoshikawa H (1998). Regulation of DNA-replication origins during cell-cycle progression. Nature 395, 618-621.
29. Zachos G, Rainey MD, and Gillespie DAF (2003). Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 22, 713-723.
30. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, and Helleday T (2005). The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7, 195-201.
31. Rodriguez R and Meuth M (2006). Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 17, 402-412.
32. Jackson DA and Pombo A (1998). Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells. J Cell Biol 140, 1285-1295.
33. Sadoni N, Cardoso MC, Stelzer EHK, Leonhardt H, and Zink D (2004). Stable chromosomal units determine the spatial and temporal organization of DNA replication. J Cell Sci 117, 5353-5365.
34. Gillespie PJ and Blow J (2010). Clusters, factories and domains: the complex structure of S-phase comes into focus. Cell Cycle 9, 3218-3226.
35. Galet C, Min L, Narayanan R, Kishi M, Weigel NL, and Ascoli M (2003). Identification of a transferable two-amino-acid motif (GT) present in the C-terminal tail of the human lutropin receptor that redirects internalized G protein-coupled receptors from a degradation to a recycling pathway. Mol Endocrinol 17, 411-422.
36. Bianchi V, Pontis E, and Reichard P (1986). Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 261, 16037-16042.
37. Palmieri D, Valentino T, D'Angelo D, De Martino I, Postiglione I, Pacelli R, Croce CM, Fedele M, and Fusco A (2011). HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene 30, 3024-3035.
38. Hombach-Klonisch S, Bialek J, Trojanowicz B, Weber E, Holzhausen H-JR, Silvertown JD, Summerlee AJ, Dralle H, Hoang-Vu C, and Klonisch T (2006). Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol 169, 617-632.
39. Olive PL, Banáth JP, and Durand RE (1990). Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells. J Natl Cancer Inst 82, 779-783.
40. Kedar PS, Stefanick DF, Horton JK, and Wilson SH (2008). Interaction between PARP-1 and ATR in mouse fibroblasts is blocked by PARP inhibition. DNA Repair (Amst) 7, 1787-1798.
41. Löffler H, Bochtler T, Fritz B, Tews BR, Ho AD, Lukas J, Bartek J, and Krämer A (2007). DNA damage-induced accumulation of centrosomal Chk1 contributes to its checkpoint function. Cell Cycle 6, 2541-2548.
42. Chen Z, Xiao Z, Chen J, Ng S-C, Sowin T, Sham H, Rosenberg S, Fesik S, and Zhang H (2003). Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2, 543-548.
43. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, and Zhang H (2004). A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 24, 1403-1411.
44. Yuwen L, Cunxin W, Congyi Z, Haixiang W, Zhiyong W, and Songsheng Q (2002). Microcalorimetric study of the metabolism of U-937 cells undergoing apoptosis induced by the combined treatment of hyperthermia and chemotherapy. J Therm Biol 27, 129-135.
45. Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, and Sezer O (2003). Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 88, 1406-1410.
46. Wang X, Liu X, Li AY-J, Chen L, Lai L, Lin HH, Hu S, Yao L, Peng J, Loera S, et al. (2011). Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res 17, 2570-2580.
47. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M, and Lage H (2006). Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118, 1699-1712.
48. Li AYJ, Boo LM, Wang S-Y, Lin HH, Wang CCC, Yen Y, Chen BPC, Chen DJ, and Ann DK (2009). Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res 69, 5699-5706.
49. Meek K, Dang V, Lees-Miller SP, and Frederick WA (2008). Advances in Immunology. Vol. 99. Academic Press, New York, NY. pp. 33-58.
50. Chen L, Liu T-H, and Walworth NC (1999). Association of Chk1 with 14-3-3 proteins is stimulated by DNA damage. Genes Dev 13, 675-685.
51. Jiang K, Pereira E, Maxfield M, Russell B, Goudelock DM, and Sanchez Y (2003). Regulation of Chk1 includes chromatin association and 14-3-3 binding following phosphorylation on Ser-345. J Biol Chem 278, 25207-25217.
52. Mochida S, Esashi F, Aono N, Tamai K, O'Connell MJ, and Yanagida M (2004). Regulation of checkpoint kinases through dynamic interaction with Crb2. EMBO J 23, 418-428.
53. Latif C, den Elzen NR, and O'Connell MJ (2004). DNA damage checkpoint maintenance through sustained Chk1 activity. J Cell Sci 117, 3489-3498.
54. Dai Y and Grant S (2010). New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16, 376-383.
55. Garrett MD and Collins I (2011). Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 32, 308-316.
56. Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall KJ, Aherne GW, Eccles SA, Raynaud FI, et al. (2010). The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther 9, 89-100.
57. Goudelock DM, Jiang K, Pereira E, Russell B, and Sanchez Y (2003). Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNAdependent protein kinase complex. J Biol Chem 278, 29940-29947.
58. Capasso H, Palermo C, Wan S, Rao H, John UP, O'Connell MJ, and Walworth NC (2002). Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest. J Cell Sci 115, 4555-4564.
59. Liu Q, Guntuku S, Cui X-S, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, et al. (2000). Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev 14, 1448-1459.
60. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, and O'Connell MJ (2001). Oncogene. Vol. 20. Nature Publishing Group, New York, NY. p. 7453.
61. Lossaint G, Besnard E, Fisher D, Piette J, and Dulic V (2011). Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/ p21 pathway is functional. Oncogene 30, 4261-4274.
62. Chen C, Kennedy R, Sidi S, Look AT, and D'Andrea A (2009). CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 8, 24.
63. Heffernan TP, Kawasumi M, Blasina A, Anderes K, Conney AH, and Nghiem P (2009). ATR-Chk1 pathway inhibition promotes apoptosis after UV treatment in primary human keratinocytes: potential basis for the UV protective effects of caffeine. J Invest Dermatol 129, 1805-1815.
64. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, and Meuth M (2009). ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 5, e1000324.
65. D'Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, Pacelli R, D'Incalci M, and Fusco A (2012). The impairment of the high mobility group A (HMGA) protein function contributes to the anticancer activity of trabectedin. Eur J Cancer. DOI: 10.1016/j.ejca.2012.10.014, E-pub ahead of print.
66. Pentimalli F, Dentice M, Fedele M, Pierantoni GM, Cito L, Pallante P, Santoro M, Viglietto G, Cin PD, and Fusco A (2003). Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. Cancer Res 63, 7423-7427.
67. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, and Tchernitsa O (2008). HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123, 348-356.
68. Nam EA and Cortez D (2011). ATR signalling: more than meeting at the fork. Biochem J 436, 527-536.
69. Cimprich KA and Cortez D (2008). ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9, 616-627.
70. Mordes DA, Glick GG, Zhao R, and Cortez D (2008). TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. Genes Dev 22, 1478-1489.
71. Lindsey-Boltz LA and Sancar A (2011). Tethering DNA damage checkpoint mediator proteins topoisomerase IIbeta-binding protein 1 (TopBP1) and Claspin to DNA activates ataxia-telangiectasia mutated and RAD3-related (ATR) phosphorylation of checkpoint kinase 1 (Chk1). J Biol Chem 286, 19229-19236.
72. Yoo HY, Kumagai A, Shevchenko A, and Dunphy WG (2007). Ataxiatelangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM. J Biol Chem 282, 17501-17506.
73. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, and Los M (2008). Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med 14, 450-460.